Editor's letter

Issue 154 • May 2025

Don’t miss out – sign up to our free industry-leading magazine and newsletters

Cover image: Woman injecting herself with Mounjaro. Credit: MKPhoto12/Shutterstock

Welcome to the latest issue of Pharmaceutical Technology Focus magazine

The astronomical rise in popularity of GLP-1RAs in recent years has led to a shortage, prompting users to turn to compounders as an alternative to the likes of Novo Nordisk’s semaglutide (Wegovy/Ozempic) and Eli Lilly’s tirzepatide (Mounjaro/Zepbound). However, in February 2025, the US Food and Drug Administration (FDA) signalled that the semaglutide and tirzepatide shortage was over.

This month’s cover feature explores what the end of the shortage means for the compounder segment, with pharmacies and outsourcing facilities now obliged to cease production in April and May respectively. Also in this issue, we look at what pharma can do to manage rising trial costs, which have risen annually since 2014. Be sure to check out our exclusive interview centred on unorthodox funding strategies for ultra-rare therapies.

All this and the latest pharma industry news, comment, and analysis from GlobalData.

Ross Law, deputy editor

Go to article: Home | The GLP-1 drug shortage is over. What’s next for the compounders?Go to article: Editor's letterGo to article: ContentsGo to article: Mimotopes Company InsightGo to article: MimotopesGo to article: MilliporeSigmaGo to article: BriefingGo to article: News in NumbersGo to article: Latest NewsGo to article: Latest DealsGo to article: Molnar-Institute Company InsightGo to article: Molnar-InstituteGo to article: ZETAGo to article: In DepthGo to article: The GLP-1 drug shortage is over. What’s next for the compounders?Go to article: Big pharma faces headwinds in China as vaccine sales declineGo to article: How can pharma manage rising trial costs?Go to article: Can AI replace medical writers? Experts say not immediatelyGo to article: Saving shelved ultra-rare therapies through unorthodox fundingGo to article: Do in vivo CAR-T cell therapies have the potential to overtake ex vivo CAR-Ts?Go to article: Weight loss implants to increase compliance and cut admin burden for patientsGo to article: Greens Company InsightGo to article: ListingsGo to article: EventsGo to article: Excellence AwardsGo to article: Buyer's GuidesGo to article: Next issue